Our Science
Hair follicle derived neural precursors.
Manufacture.
Regenerative medicine and cell therapies in particular have historically been slave to the mantra “the process is the product”.
S2N has broken those constraints by comprehensively defining HFN’s Critical Quality Attributes following FDA guidelines for purity, identity, safety, stability and potency.
Our 100% cGMP-compatible process delivers unrivaled cell quality and reliability: >90% purity across a multiplex panel of markers AND <10% line-to-line variability.
S2N is ready to support cell production for human clinical trials and commercial applications.
Biological Control.
The first step in the cell therapy journey is that donor cells need to get from their site of delivery to final destination in the brain. This process is called chemotaxis.
To date, there has been no practical method for in vivo migratory control of transplanted cells.
However, one of the stand-out features of HFNs is their chemotaxic responsiveness to a specific brain signal.
In the figure above, we measured HFN migration towards this signal and showed this can be abolished by a specific receptor blocker, proving that HFN migratory behaviour is mediated by this receptor.
We have used this insight to test if skin-derived neuroprecursors can be guided in the brain. How? By using a powerful endogenous upregulator of this signal.
In rodents, just a few weeks of signal upregulation around the time of engraftment was sufficient to increase donor cell survival and neuronal differentiation in the hippocampus by >50% and synaptic regeneration by >100%.
S2N is diving deep into this fascinating science and we are very excited about the potential for controlling donor cell destiny with a simple strategy that could be readily applied in the clinic.
Preclinical Trials.
Canine veterinary trial of our cell technology has been a strategic decision designed to move beyond rodent studies.
With this comes a need to more precisely measure and understand canine in-home behaviour. That is why Prof Valenzuela’s team developed Function Cloud, an all-new wearable device system that can track human or pet movement around the home.
In the figure above, a 24-hour movement map of one of veterinary trial participants is overlaid on their floor plan. The grey zone was found to be remarkably consistent day-on-day, in effect a ‘spatial signature’ for that dog at baseline to be able to compare with at later stages.
The hot spot in the middle of the dining area shows where this dog routinely circles, over and over, a tell-tale sign of Canine Dementia.
S2N has exclusive access to Function Cloud technology for its large-animal veterinary trials and future human trials. We are currently applying machine learning algorithms to automatically extract clinically-relevant features from this big data.
S2N is also interested in partnering with leading research groups to trial HFN cell therapy in Parkinson’s disease models and other models of neurodegenerative disease.